Abstract:Pneumonia remains the single leading cause of childhood death worldwide. Despite the commercial availability of multiple pneumococcal conjugate vaccines (PCVs), high dosage cost and supply shortages prevent PCV delivery to much of the developing world. The current work presents high-yield pneumococcal conjugates that are immunogenic in animals and suitable for use in human vaccine development. The 13-valent pneumococcal conjugate vaccine (PCV-13) investigated in this research incorporated serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Pneumococcal polysaccharides (PnPSs) and CRM197 carrier protein were produced and purified in-house, and used to prepare PnPS-CRM conjugates using unique, cyanide-free, in vacuo glycation conjugation methods. In vitro characterization confirmed the generation of higher molecular weight PnPS-CRM conjugates low in free protein. In vivo animal studies were performed to compare PnuVax's PCV-13 to the commercially available PCV-13, Prevnar®13 (Pfizer, USA). A boost dose was provided to all groups post-dose 1 at t = 14 days. Post-dose 2 results at t = 28 days showed that all 13 serotypes in PnuVax's PCV-13 were boostable. Per serotype IgG GMCs demonstrated that PnuVax's PCV-13 is immunogenic for all 13 serotypes, with 10 of the 13 serotypes statistically the same or higher than Prevnar®13 post-dose 2. As a result, the novel polysaccharide-protein conjugates developed in this work are highly promising for use in human PCV development. The in vacuo conjugation technique applied in this work could also be readily adapted to develop many other conjugate vaccines.

Development of Streptococcus pneumoniae Vaccines Using Live Vectors

Methods and Clinical Development of Adenovirus-Vectored Vaccines Against Mucosal Pathogens

A Concise Review of Vaccines Against Mycoplasma Hyopneumoniae

Non-capsular based immunization approaches to prevent Streptococcus pneumoniae infection

Advances in the Research of New Pneumococcal Vaccines

Pneumonia and Streptococcus pneumoniae vaccine

Current Stage in the Development of Klebsiella pneumoniae Vaccines

Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine

Current trends in development and manufacturing of higher-valent pneumococcal polysaccharide conjugate vaccine and its challenges

Mycoplasma pneumoniae Infections: Pathogenesis and Vaccine Development

Pneumococcal Immunization Strategies for High-Risk Pediatric Populations Worldwide: One Size Does Not Fit All

Development of an Efficacious, Semisynthetic Glycoconjugate Vaccine Candidate against Streptococcus pneumoniae Serotype 1

The Evolution of Vaccines Development across Salmonella Serovars among Animal Hosts: A Systematic Review

Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines

Gamma-irradiation of Streptococcus pneumoniae for the use as an immunogenic whole cell vaccine

[Current and new vaccines against pneumococci]

Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae

Current Status of Poultry Recombinant Virus Vector Vaccine Development

Streptococcus pneumoniae’s Virulence and Host Immunity: Aging, Diagnostics, and Prevention

A Nonadjuvanted Whole-Inactivated Pneumococcal Vaccine Induces Multiserotype Opsonophagocytic Responses Mediated by Noncapsule-Specific Antibodies

An intranasal cationic liposomal polysaccharide vaccine elicits humoral immune responses against Streptococcus pneumoniae